BR0307906A - Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 - Google Patents

Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2

Info

Publication number
BR0307906A
BR0307906A BR0307906-6A BR0307906A BR0307906A BR 0307906 A BR0307906 A BR 0307906A BR 0307906 A BR0307906 A BR 0307906A BR 0307906 A BR0307906 A BR 0307906A
Authority
BR
Brazil
Prior art keywords
alpha
inhibitor
combinations
delta
selective cyclooxygenase
Prior art date
Application number
BR0307906-6A
Other languages
English (en)
Inventor
Charles Price Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0307906A publication Critical patent/BR0307906A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMBINAçõES DE UM LIGANDO ALFA-2-DELTA COM UM INIBIDOR SELETIVO DE CICLOOXIGENASE-2". A presente invenção refere-se a uma combinação compreendendo um inibidor seletivo de COX-2, ou um seu sal farmaceuticamente aceitável, e um ligando Alfa-2-delta, ou um seu sal farmaceuticamente aceitável, e valdecoxib. Exemplos de inibidores seletivos de COX-2 incluem, valdecoxib, rofecoxib e celecoxib. Exemplos de ligandos Alfa-2-delta incluem gabapentina, pregabalina, ácido (3S,4S)-(1-aminometil-3,4-dimetilciclopentil)-acético e cloridrato de 3-(1-aminometilciclohexilmetil)-4H-[1,2,4]oxadiazol5-ona. As combinações são úteis para o tratamento de certas doenças incluindo lesão da cartilagem, inflamação, dor e artrite.
BR0307906-6A 2002-02-22 2003-02-12 Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 BR0307906A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19
PCT/IB2003/000534 WO2003070237A1 (en) 2002-02-22 2003-02-12 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
BR0307906A true BR0307906A (pt) 2004-12-21

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307906-6A BR0307906A (pt) 2002-02-22 2003-02-12 Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2

Country Status (21)

Country Link
US (1) US20030199567A1 (pt)
EP (1) EP1480639A1 (pt)
JP (1) JP2005523281A (pt)
KR (1) KR20040085216A (pt)
CN (1) CN1635887A (pt)
AR (1) AR038531A1 (pt)
AU (1) AU2003246864A1 (pt)
BR (1) BR0307906A (pt)
CA (1) CA2476438A1 (pt)
CO (1) CO5611109A2 (pt)
HN (1) HN2003000071A (pt)
IL (1) IL162932A0 (pt)
MX (1) MXPA04008175A (pt)
NO (1) NO20043947L (pt)
PA (1) PA8567201A1 (pt)
PE (1) PE20031052A1 (pt)
PL (1) PL372210A1 (pt)
RU (1) RU2286151C2 (pt)
TW (1) TW200303214A (pt)
UY (1) UY27675A1 (pt)
WO (1) WO2003070237A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
KR100828218B1 (ko) * 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1682149B1 (en) * 2003-10-23 2009-12-02 Medtronic, Inc. Injectable gabapentin compositions
TW200806627A (en) * 2006-04-11 2008-02-01 Novartis Ag Organic compounds
BRPI0718874A2 (pt) * 2006-12-22 2015-06-23 Novartis Ag Compostos orgânicos
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
PE20110291A1 (es) * 2008-09-05 2011-06-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
US20220125773A1 (en) * 2020-10-28 2022-04-28 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
ATE311867T1 (de) * 1997-09-08 2005-12-15 Warner Lambert Co Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
AU759392B2 (en) * 1997-12-16 2003-04-10 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
AU1930301A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Valdecoxib compositions

Also Published As

Publication number Publication date
MXPA04008175A (es) 2004-11-26
EP1480639A1 (en) 2004-12-01
RU2286151C2 (ru) 2006-10-27
HN2003000071A (es) 2003-11-24
PE20031052A1 (es) 2003-12-24
PA8567201A1 (es) 2003-11-12
RU2004125609A (ru) 2006-01-27
IL162932A0 (en) 2005-11-20
NO20043947L (no) 2004-09-21
AR038531A1 (es) 2005-01-19
CN1635887A (zh) 2005-07-06
TW200303214A (en) 2003-09-01
AU2003246864A1 (en) 2003-09-09
KR20040085216A (ko) 2004-10-07
PL372210A1 (en) 2005-07-11
UY27675A1 (es) 2003-09-30
CO5611109A2 (es) 2006-02-28
US20030199567A1 (en) 2003-10-23
CA2476438A1 (en) 2003-08-28
WO2003070237A1 (en) 2003-08-28
JP2005523281A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
BR0307906A (pt) Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2
Li et al. Citrullinated histone H3: a novel target for the treatment of sepsis
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
NO20042148L (no) Cyklooksygenase-2 inhibitor/histondeacetylaseinhibitorkombinasjon
ATE482699T1 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson
DE69637985D1 (de) Protonenpumpeninhibitoren enthaltendes arzneimittel
EA200100905A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
WO2007131364A8 (en) Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
BRPI0720500A8 (pt) Preparação líquida transdérmica
EP1627639A3 (en) Use of COX-2 inhibitors for the treatment of affective disorders
EA200500941A1 (ru) Средство для лечения болезней суставов
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
EA200702280A1 (ru) Синергические комбинации
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
Eren et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids
EA200500942A1 (ru) Средство для лечения болезней суставов
EA200300940A1 (ru) Энтеральные соли кетокислот и аминокислот
RU2006109966A (ru) Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных
BR0312943A (pt) Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
WO2004006931A3 (en) Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2
BRPI0415630A (pt) suspensões analgésicas para liberação controlada
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/42; A61P 29/00

Ipc: A61K 31/42 (2011.01), A61P 29/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.